Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Regorafenib
Treatment for Colon and rectum cancer
Typical Dosage: 160 mg orally once daily for 3 weeks, followed by 1 week off, every 4 weeks
Effectiveness
50%
Safety Score
30%
Clinical Trials
10
Participants
7K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
160 mg orally once daily for 3 weeks, followed by 1 week off, every 4 weeks
Time to Effect
2-4 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$8,000
Side Effect Mgmt:$7,000
Total Annual:$195,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$400,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$3,900,000
Cost per Remission
$19,500,000
Comparison vs Best Supportive Care
Cost Difference
+$195,000/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Regorafenib in Colon and rectum cancer
Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer
NCT06865521ACTIVE NOT RECRUITINGNA
22 participants
INTERVENTIONAL
Chengdu, China +1 more
Started: Feb 21, 2025
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
NCT07003022RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Shanghai, China
Started: Jun 1, 2025
Completed Clinical Trials
5 completed trials for Regorafenib in Colon and rectum cancer
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
NCT04534218COMPLETEDPHASE2
49 participants
INTERVENTIONAL
Besançon, France +2 more
Started: Oct 16, 2020
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
NCT04362839COMPLETEDPHASE1
39 participants
INTERVENTIONAL
Duarte, United States
Started: May 27, 2020
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
NCT04126733COMPLETEDPHASE2
70 participants
INTERVENTIONAL
Duarte, United States +14 more
Started: Oct 14, 2019
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
NCT05839951COMPLETED
818 participants
OBSERVATIONAL
Whippany, United States
Started: Apr 24, 2023
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
NCT03251378COMPLETEDPHASE1
129 participants
INTERVENTIONAL
Phoenix, United States +8 more
Started: Dec 11, 2017